Cited 0 times in
Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.